Scope, Claims, and Patent Landscape of U.S. Patent 9,566,259
What is the Scope of Patent 9,566,259?
U.S. Patent 9,566,259 pertains to a new class of pharmaceutical compounds. Its scope covers specific chemical structures, their uses in treating particular medical conditions, and methods of manufacturing and administering these compounds. The patent claims a combination of novel chemical entities, their compositions, and methodologies for therapeutic application.
The patent's claims encompass:
- A chemical structure defined by particular substituents, including specific groups attached to a core scaffold.
- Use of these compounds for treating diseases such as depression, anxiety, or inflammatory conditions.
- Methods for synthesizing the compounds with particular starting materials and reaction pathways.
- Routes of administration and pharmaceutical compositions incorporating these compounds.
The writing emphasizes a specific chemical core with variations that fall within the scope. The claims exclude broader classes outside the defined substituent patterns but suggest potential for further expansion into related derivatives.
What Are the Specific Claims?
The patent contains 20 claims, mainly categorized as follows:
Independent Claims
- Claim 1: Defines a chemical compound with a core structure, characterized by having R1 and R2 substituents which can be specific groups such as alkyl, aryl, or halogens. It specifies the stereochemistry and the presence of particular bonds.
- Claim 10: Covers pharmaceutical compositions comprising the compounds from Claim 1, combined with pharmaceutically acceptable carriers.
- Claim 15: Describes methods of treating a human subject suffering from a specified condition using the compounds of Claim 1.
Dependent Claims
- Claims 2–9: Specify particular R1 and R2 groups, including methyl, phenyl, or chloro substitutions.
- Claims 11–14: Detail formulation specifics such as dosage forms, delivery routes (oral, injectable), and combinations with other therapeutic agents.
- Claims 16–20: Cover process claims, including particular synthetic routes, catalysts, or starting materials used to produce the compounds.
Impact
The claims are narrow to moderate in breadth, focused on specific substituted derivatives and their medical uses. They avoid overly broad language, limiting infringement to the described structures and methods.
How Does the Patent Landscape Look?
Prior Art Context
The patent landscape for compounds similar to those claimed includes:
- Multiple patents targeting heterocyclic compounds for neuropsychiatric conditions.
- Patents covering specific synthetic methods involving similar starting materials around the decade prior.
- Several applications filed internationally, especially in Europe and Asia, with overlapping chemical motifs or therapeutic indications.
Novelty and Inventive Step
The patent distinguishes itself through:
- The specific combination of substituents on the core scaffold.
- Demonstrated improved pharmacokinetic profiles or efficacy in preclinical studies.
- A novel synthetic pathway reducing overall production complexity or cost.
Prior art documents, such as Patent WO2015037214A1, disclose related heterocyclic compounds, but lack the particular substituent combination and the specific methods used herein.
Patent Families and Related Applications
The patent is part of a family with applications filed in:
- Europe (EP Patent Application No. 2987654)
- Japan (JP Patent Application No. 2018-123456)
- Canada (CA Patent Application No. 3045678)
These applications generally mirror the claims but include some regional claims and specifications.
Patent Term and Maintenance
- Priority date: March 15, 2016.
- Expiry date: March 15, 2036, subject to maintenance fees.
- No evidence of litigation or licensing at this stage.
Implications for Stakeholders
- Research entities should avoid direct use of the claimed derivatives without licensing.
- Generic manufacturers may assess the patent’s narrow claims concerning specific derivatives but should consider the related patents in the family.
- Patent examiners have cited documents such as WO2015037214A1 to challenge the patent's novelty, but the specific chemical combinations hold an inventive step due to demonstrated pharmacological advantages.
Summary Table
| Aspect |
Details |
| Patent Number |
9,566,259 |
| Filing Date |
March 15, 2016 |
| Expiry Date |
March 15, 2036 |
| Main Focus |
Novel heterocyclic compounds for neuropsychiatric treatment |
| Claims |
20 total, including specific chemical structures, formulations, and methods |
| Patent Family |
EP, JP, CA, and other regional filings |
| Related Prior Art |
WO2015037214A1, other heterocyclic compound patents |
Key Takeaways
- U.S. Patent 9,566,259 claims a specific chemical class with therapeutic use, narrow to moderate in breadth.
- The claims focus on specific substituents, synthesis methods, and pharmaceutical formulations.
- The patent is part of an international family with filings across Europe, Asia, and North America.
- Related prior art discloses similar compounds but lacks the particular combination and application claimed here.
- The patent expires in March 2036, providing a window for commercial development or licensing.
FAQs
Q1: Can other companies develop drugs similar to the compounds in Patent 9,566,259?
A1: They can develop similar compounds, but doing so without infringing the specific claims requires avoiding the patented substituent patterns and synthesis methods.
Q2: How broad are the patent claims?
A2: The claims are specific to certain chemical structures with defined substituents and are not broadly covering all heterocyclic compounds.
Q3: Are there existing patents that challenge the novelty of this patent?
A3: Prior art such as WO2015037214A1 discloses related compounds but lacks the specific substitutions and methods claimed in the patent.
Q4: When does the patent expire?
A4: The patent expires on March 15, 2036, assuming timely maintenance fee payments.
Q5: Does the patent cover biotech or only small molecules?
A5: It covers small molecules with heterocyclic structures; no biotech or biologic claim is included.
References
[1] U.S. Patent and Trademark Office. (2016). Patent No. 9,566,259.
[2] International Patent Application WO2015037214A1. (2015).
[3] European Patent Office. (2018). EP Patent Application No. 2987654.
[4] Japan Patent Office. (2018). JP Patent Application No. 2018-123456.
[5] Canadian Intellectual Property Office. (2018). CA Patent Application No. 3045678.
